Cancer Immunotherapy Might Benefit From Previously Overlooked Immune Players
Health & BehaviorUsing a bioinformatics approach, University of California San Diego School of Medicine researchers found that CD4+ T cell’s binding partner, a molecule called MHC-II, may have even more influence on emerging tumors than MHC-I, the better known partner of CD8+ T cells. The finding, published September 20 in Cell, may help researchers improve cancer immunotherapies and predict which patients will respond best.